C. A. Ford

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo

This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.

Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity

This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.

Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.

CXCR2 inhibition enables NASH-HCC immunotherapy

This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.

THEM6-mediated lipid remodelling sustains stress resistance in cancer

This study identifies THEM6 as a marker of ADT resistance in prostate cancer, showing its role in lipid homeostasis and stress response, and highlights it as a potential therapeutic target.

Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism

This study identifies cyclocreatine as a dual-action inhibitor of prostate cancer by blocking the phosphagen system and increasing S-adenosyl methionine levels.